Page 35 - 南京医科大学学报自然科学版
P. 35
第43卷第2期 朱伯谦,宋兵战,陈 凯,等. DNA甲基化调控p16表达在替格瑞洛改善血管内皮功能中的
2023年2月 作用及机制[J]. 南京医科大学学报(自然科学版),2023,43(2):169-178 ·177 ·
往p16研究主要集中在肿瘤领域,p16蛋白表达水平 Cerebrovasc Dis,2021,30(2):105520
可作为多种恶性肿瘤预后的预测指标 [17] 。近年来, [5] ZHOU Z. Purinergic interplay between erythrocytes and
p16在动脉粥样硬化领域也逐渐受到重视,p16在动 platelets in diabetes⁃associated vascular dysfunction[J].
脉粥样硬化斑块中异常表达,且与斑块稳定性密切 Purinergic Signal,2021,17(4):705-712
[6] GUNAWARDENA T,MERINOPOULOS I,WICKRAMA⁃
相关 [18] 。既往研究也发现p16表达在过氧化氢诱导
RACHCHI U,et al. Endothelial dysfunction and coronary
的 HUVEC 衰老中也发挥重要作用 [19] 。本研究中,
vasoreactivity ⁃ a review of the history,physiology,diag⁃
替格瑞洛干预HUVEC后p16表达显著降低,而过表 nostic techniques,and clinical relevance[J]. Curr Cardi⁃
达p16可逆转替格瑞洛对ox⁃LDL 诱导的HUVEC 增 ol Rev,2021,17(1):85-100
殖迁移、凋亡的影响,提示p16基因在替格瑞洛调控 [7] LEON K E,TANGUDU N K,AIRD K M,et al. Loss of
内皮细胞功能中同样发挥重要作用。 p16:A bouncer of the immunological surveillance?[J].
目前认为 p16 表达异常主要与 p16 基因的缺 Life(Basel),2021,11(4):309
失、突变和DNA甲基化有关。DNA甲基化是基因组 [8] PIRILLO A,NORATA G D,CATAPANO A L. LOX⁃1,
OxLDL,and atherosclerosis[J]. Mediators Inflamm,
DNA一种主要表观遗传修饰方式,能在不改变DNA
2013,2013:152786
序列的前提下改变遗传性状,是调控基因组功能状态
[9] AL⁃ABDOUH A,BARBARAWI M,ABUSNINA W,et al.
的重要手段 [19] 。在哺乳动物中,DNA 甲基化由 3 种
Prasugrel vs ticagrelor for DAPT in patients with ACS un⁃
DNA 甲 基 化 转 移 酶(DNA methyltransferases,DN⁃ dergoing PCI:a systematic review and meta ⁃ analysis of
[21]
MTs)催化:DNMT1,DNMT3A 和 DNMT3B 。DN⁃ randomized controlled trials[J]. Cardiovasc Revasc Med,
MT1 是主要的维持性 DNA 甲基化转移酶,DNMT3A 2020,21(12):1613-1618
和 DNMT3B 是从头合成性 DNA 甲基化转移酶 [22] 。 [10] KANG M,SHAO S,ZHANG Y,et al. Beneficial effects of
DNA 甲基化调控基因表达,影响 DNA 修复、细胞生 ticagrelor on oxidized low⁃density lipoprotein(ox⁃ldl)⁃in⁃
长、分化、增殖以及肿瘤发生等过程 [21] 。我们既往 duced apoptosis in human umbilical vein endothelial cells
[J]. Med Sci Monit,2019,25:9811-9819
研究证实 p16 基因表达受 DNMT1 介导 DNA 甲基化
[11] TORNGREN K,OHMAN J,SALMI H,et al. Ticagrelor
调控 [23] 。本研究发现在 ox⁃LDL 诱导的 HUVEC 中,
improves peripheral arterial function in patients with a
DNMT1 可调控 p16 启动子区的甲基化水平并影响 previous acute coronary syndrome[J]. Cardiology,2013,
其表达,而替格瑞洛可通过DNMT1/p16信号通路发 124(4):252-258
挥保护内皮功能的作用。 [12] BONELLO L,FRERE C,COINTE S,et al. Ticagrelor in⁃
综上所述,本研究证明替格瑞洛可通过DNMT1 creases endothelial progenitor cell level compared to clop⁃
介导的DNA甲基化调控p16表达,进而减轻ox⁃LDL idogrel in acute coronary syndromes:a prospective ran⁃
诱导的HUVEC损伤,改善血管内皮功能。 domized study[J]. Int J Cardiol,2015,187:502-507
[13] 谭晓晖,刘杰强,梁转合,等. 替格瑞洛对急性冠状动脉
[参考文献]
综合征患者外周血管内皮功能的影响[J]. 临床心血管
[1] WERNLY B,ERLINGE D,PERNOW J,et al. Ticagrelor: 病杂志. 2015,31(7):728-732
a cardiometabolic drug targeting erythrocyte⁃mediated pu⁃ [14] MOULIAS A,XANTHOPOULOU I,ALEXOPOULOS D.
rinergic signaling?[J]. Am J Physiol Heart Circ Physiol, Does ticagrelor improve endothelial function?[J]. J Car⁃
2021,320(1):H90-H94 diovasc Pharmacol Ther,2019,24(1):11-17
[2] WALLENTIN L,BECKER R C,BUDAJ A,et al. Ticagre⁃ [15] KAMB A,GRUIS N A,WEAVER⁃FELDHAUS J,et al. A
lor versus clopidogrel in patients with acute coronary syn⁃ cell cycle regulator potentially involved in genesis of
dromes[J]. N Engl J Med,2009,361(11):1045-1057 many tumor types[J]. Science,1994,264(5157):436-
[3] COLLET J P,THIELE H,BARBATO E,et al. 2020 ESC 440
Guidelines for the management of acute coronary syn⁃ [16] PEZZUTO A,D'ASCANIO M,RICCI A,et al. Expression
dromes in patients presenting without persistent ST⁃seg⁃ and role of p16 and GLUT1 in malignant diseases and
ment elevation[J]. Eur Heart J,2021,42(14):1289- lung cancer:a review[J]. Thorac Cancer,2020,11(11):
1367 3060-3070
[4] LANDZBERG D R,ENGLISH S,FRANKEL M,et al. [17] ZHAO R,CHOI B Y,LEE M H,et al. Implications of ge⁃
Stroke thrombolysis in patients taking ticagrelor ⁃two suc⁃ netic and epigenetic alterations of CDKN2A (p16
cessful cases and a review of the literature[J]. J Stroke (INK4a))in cancer[J]. EBioMedicine 2016,8:30-39